Research graph
References from Gastrin and cholecystokinin 2 receptor, and gastrin-releasing peptide receptor in cancer: From pathogenesis to precision medicine. Local targets link to admitted publications; unresolved targets remain external evidence.
Human colorectal cancers express a constitutively active cholecystokinin-B/gastrin receptor that stimulates cell growth
10.1074/jbc.m005754200 · 2000 · External reference
Gastrin and gastric cancer
10.1016/j.jcmgh.2017.03.004 · 2017 · External reference
Gastrin: from physiology to gastrointestinal malignancies
10.1093/function/zqab062 · 2021 · External reference
Gastrin stimulates the growth of gastric pit cell precursors by inducing its own receptors
10.1152/ajpgi.00117.2001 · 2002 · External reference
Promoting role of cholecystokinin 2 receptor (CCK2R) in gastrointestinal stromal tumour pathogenesis
10.1002/path.4071 · 2012 · External reference
Gastrin receptor pharmacology
10.1007/s11894-012-0293-1 · 2012 · External reference
Assessment of cholecystokinin 2 receptor (CCK2R) in neoplastic tissue
10.18632/oncotarget.7522 · 2016 · External reference
Insights into effects/risks of chronic hypergastrinemia and lifelong PPI treatment in man based on studies of patients with Zollinger–Ellison syndrome
10.3390/ijms20205128 · 2019 · External reference
Gastrin stimulates a cholecystokinin-2-receptor-expressing cardia progenitor cell and promotes progression of Barrett’s-like esophagus
10.18632/oncotarget.10667 · 2017 · External reference
Expression cloning and characterization of the canine parietal cell gastrin receptor
10.1073/pnas.89.8.3605 · 1992 · External reference
Gastric acid secretion in the totally isolated, vascularly perfused rat stomach. A selective muscarinic-1 agent does, whereas gastrin does not, augment maximal histamine-stimulated acid secretion
10.3109/00365528709011147 · 1987 · External reference
Gastrin has a specific proliferative effect on the rat enterochromaffin-like cell, but not on the parietal cell: a study by elutriation centrifugation
10.1046/j.1365-201x.2000.00688.x · 2000 · External reference
Perspectives on gastric cancer: the central role of gastrin in carcinogenesis by Helicobacter pylori, oxyntic atrophy and drug-induced acid suppression
10.3389/fonc.2026.1807681 · 2026 · External reference
Pathophysiology of gastric NETs: role of gastrin and menin
10.1007/s11894-017-0572-y · 2017 · External reference
Exploiting cancer’s phenotypic guise against itself: targeting ectopically expressed peptide G-protein coupled receptors for lung cancer therapy
10.18632/oncotarget.18403 · 2017 · External reference
Proton pump inhibitors and risk of gastric cancer: a population-based cohort study
10.1038/sj.bjc.6605024 · 2009 · External reference
Systematic review: the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology
10.1111/apt.13324 · 2015 · External reference
Zinc ions mediate gastrin expression, proliferation, and migration downstream of the cholecystokinin-2 receptor
10.1210/en.2016-1270 · 2016 · External reference
Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study
10.1136/gutjnl-2017-314605 · 2018 · External reference
Unresolved reference
External reference
Expression of the cholecystokinin-B receptor in neoplastic gastric cells
10.1007/s12672-017-0311-8 · 2018 · External reference
Types of gastric carcinomas
10.3390/ijms19124109 · 2018 · External reference
Correct identification of cell of origin may explain many aspects of cancer: the role of neuroendocrine cells as exemplified from the stomach
10.3390/ijms21165751 · 2020 · External reference
CCK2R antagonists: from SAR to clinical trials
10.1016/j.drudis.2020.05.008 · 2020 · External reference
Cholecystokinin-2 receptor targeting with radiolabeled peptides: current status and future directions
10.2174/0929867327666200625143035 · 2020 · External reference
Update on preclinical development and clinical translation of cholecystokinin-2 receptor targeting radiopharmaceuticals
10.3390/cancers13225776 · 2021 · External reference
Utilizing peptide ligand GPCRs to image and treat pancreatic cancer
10.3390/biomedicines6020065 · 2018 · External reference
Theranostic prospects of gastrin-releasing peptide receptor–radioantagonists in oncology
10.1016/j.cpet.2017.02.007 · 2017 · External reference
Novel insight on GRP/GRPR axis in diseases
10.1016/j.biopha.2023.114497 · 2023 · External reference
Progastrin-releasing peptide as a diagnostic biomarker of pulmonary and non-pulmonary neuroendocrine neoplasms
10.1080/07435800.2024.2365895 · 2024 · External reference
Gastrin-releasing peptide receptor (GRPR) as a novel biomarker and therapeutic target in prostate cancer
2024 · External reference
Gastrin releasing peptide receptors-targeted PET diagnostics and radionuclide therapy for prostate cancer management
10.1016/j.cpet.2024.03.004 · 2024 · External reference
CCK2R identifies and regulates gastric antral stem cell states and carcinogenesis
10.1136/gutjnl-2014-307190 · 2015 · External reference
Progastrin: an overview of its crucial role in the tumorigenesis of gastrointestinal cancers
10.3390/biomedicines12040885 · 2024 · External reference
Gastrin and upper GI cancers
10.1016/j.coph.2016.08.013 · 2016 · External reference
Structure of a human gastrin gene
10.1073/pnas.81.4.1067 · 1984 · External reference
Structural analysis of the gene encoding human gastrin: the large intron contains an Alu sequence
10.1073/pnas.81.15.4662 · 1984 · External reference
Gastrin, cholecystokinin, signaling, and biological activities in cellular processes
10.3389/fendo.2020.00112 · 2020 · External reference
Pathways of processing of the gastrin precursor in rat antral mucosa
10.1172/jci117839 · 1995 · External reference
The new biology of gastrointestinal hormones
10.1152/physrev.1998.78.4.1087 · 1998 · External reference
Clearance and acid-stimulating action of human big and little gastrins in duodenal ulcer subjects
10.1172/jci108379 · 1976 · External reference
Valine-286 residue in the third intracellular loop of the cholecystokinin 2 receptor exerts a pivotal role in cholecystokinin 2 receptor mediated intracellular signal transduction in human colon cancer cells
10.1016/j.cellsig.2005.03.009 · 2005 · External reference
The role of gasotransmitters in gut peptide actions
10.3389/fphar.2021.720703 · 2021 · External reference
The cytoprotective protein clusterin is overexpressed in hypergastrinemic rodent models of oxyntic preneoplasia and promotes gastric cancer cell survival
10.1371/journal.pone.0184514 · 2017 · External reference
The application of transgenic and gene knockout mice in the study of gastric precancerous lesions
10.1016/j.prp.2018.10.022 · 2018 · External reference
Proton pump inhibitor use, hypergastrinemia, and gastric carcinoids—what is the relationship?
10.3390/ijms21020662 · 2020 · External reference
Trophic effect of gastrin on the enterochromaffin like cells of the rat stomach: establishment of a dose response relationship
10.1136/gut.33.10.1303 · 1992 · External reference
Mucosal argyrophil endocrine cells in pernicious anaemia and upper gastrointestinal carcinoid tumours
10.1136/jcp.42.4.371 · 1989 · External reference
Towards understanding of gastric cancer based upon physiological role of gastrin and ECL cells
10.3390/cancers12113477 · 2020 · External reference
The central role of gastrin in gastric cancer
10.3389/fonc.2023.1176673 · 2023 · External reference
The most recent insights into the roots of gastric cancer
10.3390/life14010095 · 2024 · External reference
Genetically engineered mouse models in gastric precancerous lesions research
10.4240/wjgs.v17.i7.107610 · 2025 · External reference
Unresolved reference
2026 · External reference
Gastrin and cancer: a review
10.1016/j.canlet.2005.06.025 · 2006 · External reference
Hormonal suppression of stem cells inhibits symmetric cell division and gastric tumorigenesis
10.1016/j.stem.2020.01.020 · 2020 · External reference
Tumor microenvironment in gastric cancers
10.1111/cas.14521 · 2020 · External reference
Recapitulating human gastric cancer pathogenesis: experimental models of gastric cancer
2016 · External reference
The central role of gastrin in Helicobacter pylori gastric carcinogenesis
10.1080/00365521.2025.2509094 · 2025 · External reference
Helicobacter pylori and gastric acid: an intimate and reciprocal relationship
10.1177/1756283x16663395 · 2016 · External reference
Gastrointestinal neuroendocrine tumors in 2020
10.4251/wjgo.v12.i8.791 · 2020 · External reference
Neuroendocrine neoplasms of the stomach. Update on diagnostic criteria, classification, and prognostic markers
10.1007/s00428-025-04340-x · 2026 · External reference
Gastric neuroendocrine neoplasms: a review
10.12998/wjcc.v9.i27.7973 · 2021 · External reference
Potential clinical indications for a CCK2 receptor antagonist
10.1016/j.coph.2016.09.002 · 2016 · External reference
Management of gastric neuroendocrine tumors: a review
10.1245/s10434-023-14712-9 · 2024 · External reference
Gastrin induces proliferation in Barrett’s metaplasia through activation of the CCK2 receptor
10.1053/gast.2003.50091 · 2003 · External reference
Helicobacter pylori extract induces nuclear factor-kappa B, activator protein-1, and cyclooxygenase-2 in esophageal epithelial cells
10.1016/j.gassur.2005.09.003 · 2006 · External reference
Novel gastrin receptors mediate mitogenic effects of gastrin and processing intermediates of gastrin on Swiss 3T3 fibroblasts: absence of detectable cholecystokinin (CCK)-A and CCK-B receptors *
10.1074/jbc.270.15.8429 · 1995 · External reference
Gastrin and gastrin receptor antagonists bind to both N- and C-terminal halves of the 78 kDa gastrin-binding protein
10.1016/s1357-2725(96)00066-0 · 1996 · External reference
Annexin II binds progastrin and gastrin-like peptides, and mediates growth factor effects of autocrine and exogenous gastrins on colon cancer and intestinal epithelial cells
10.1038/sj.onc.1209798 · 2007 · External reference
Advantages and disadvantages of long-term proton pump inhibitor use
10.5056/jnm18001 · 2018 · External reference
The human gastrin-releasing peptide receptor gene structure, its tissue expression and promoter
10.1016/s0378-1119(00)00596-5 · 2001 · External reference
Prostate cancer theranostics targeting gastrin-releasing peptide receptors
10.1007/s11307-017-1151-1 · 2018 · External reference
Bombesin-targeted PET of prostate cancer
10.2967/jnumed.115.170977 · 2016 · External reference
Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden
10.1136/bmjopen-2017-017739 · 2017 · External reference
Endoscopic findings and outcomes of gastric mucosal changes relating to potassium-competitive acid blocker and proton pump inhibitor therapy
10.1002/deo2.400 · 2025 · External reference
Gastrin and gastric cancer
10.3389/fendo.2017.00001 · 2017 · External reference
Proton pump inhibitors and cancer: current state of play
10.3389/fphar.2022.798272 · 2022 · External reference
Risk of gastric and oesophageal adenocarcinoma following discontinuation of long-term proton-pump inhibitor therapy
10.1007/s00535-022-01930-3 · 2022 · External reference
Long term use of proton pump inhibitors and risk of stomach cancer: population based case-control study in five Nordic countries
10.1136/bmj-2025-086384 · 2026 · External reference
A meta-analysis of the effects of proton pump inhibitors on the risk of gastric cancer
2025 · External reference
Side effects of long-term proton pump inhibitor use: a review
10.1111/bcpt.13023 · 2018 · External reference
Problems associated with deprescribing of proton pump inhibitors
10.3390/ijms20215469 · 2019 · External reference
Comparing proton pump inhibitors and emerging acid-suppressive therapies in gastroesophageal reflux disease: a systematic review
2025 · External reference
The role of gastric microbiota in gastric cancer
10.1080/19490976.2020.1762520 · 2020 · External reference
Non-invasive markers for the detection of gastric precancerous conditions
10.3390/cancers16122254 · 2024 · External reference
Biochemical markers for neuroendocrine tumors: traditional circulating markers and recent development—a comprehensive review
10.3390/diagnostics14121289 · 2024 · External reference
Pro-gastrin-releasing peptide (ProGRP) as a biomarker in small-cell lung cancer diagnosis, monitoring and evaluation of treatment response
10.2147/lctt.s149516 · 2017 · External reference
Current status of radiopharmaceuticals for the theranostics of neuroendocrine neoplasms
10.3390/ph10010030 · 2017 · External reference
Unresolved reference
External reference
Potential targets other than PSMA for prostate cancer theranostics: a systematic review
10.3390/jcm10214909 · 2021 · External reference
Molecular imaging of prostate cancer
10.1148/rg.2016150059 · 2016 · External reference
GRPR-targeting radiotheranostics for breast cancer management
10.3389/fmed.2023.1250799 · 2023 · External reference
Molecular targets and the emerging role of copper radionuclides in prostate cancer theranostics
10.1186/s13550-025-01325-4 · 2025 · External reference
Gastrin-releasing peptide receptor as a theranostic target in breast cancer: a systematic scoping review
10.1053/j.semnuclmed.2024.01.004 · 2024 · External reference
GRPR expression in metastatic cancers: a review of potential application of GRPR-radioligand therapy
10.1053/j.semnuclmed.2025.07.003 · 2025 · External reference
Radiolabeled bombesin derivatives for preclinical oncological imaging
10.1016/j.biopha.2016.12.083 · 2017 · External reference
Localization of 99mTc-GRP analogs in GRPR-expressing tumors: effects of peptide length and neprilysin inhibition on biological responses
10.3390/ph12010042 · 2019 · External reference
Comparative in vitro and in vivo evaluation of two 64Cu-labeled bombesin analogs in a mouse model of human prostate adenocarcinoma
10.1016/j.nucmedbio.2005.12.011 · 2006 · External reference
Transformation to neuroendocrine phenotype in non-small-cell lung carcinoma: a literature review
10.3390/ijms26115096 · 2025 · External reference
Emerging PET imaging agents and targeted radioligand therapy: a review of clinical applications and trials
10.3390/tomography11080083 · 2025 · External reference
